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 ABSTRACT 
Objective. Vortioxetine is a novel antidepressant whose safety, tolerability and therapeutic 
action have been supported by several studies. The present naturalistic study aimed to 
characterize its effectiveness, tolerability and dropout rate in the real world. Methods. Total 
sample consisted of 66 outpatients with major depressive episode, treated with vortioxetine, 
whose clinical variables were evaluated over three time points. Results. Most common 
primary diagnoses were Major Depressive Disorder (45.5%) and Bipolar Disorder (33.4%), 
with an overall comorbidity rate of 48.5% and concomitant medications in the 89.4%. The 
mean vortioxetine daily dosage was 12.90±5.65mg. Effectiveness of vortioxetine through a 
significant improvement on specific psychometric scales emerged, while only a non significant 
trend of association between higher dosage and effectiveness was found. In the total sample 
the 51.5% was classified as responder, the 36.4% as remitter. Two thirds of subjects did not 
report side effects, while, in the reminder patients, gastrointestinal ones were the most 
frequent (72.7%). Almost two thirds of the sample could complete the follow up, while the 
36.4% dropped out; the main reasons of dropout were side effects (37.5%) and lack of efficacy 
(29.2%). Conclusions.Larger sample studies are warranted to better characterize 
vortioxetine effectiveness and tolerability in the real world.  
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1. INTRODUCTION 
Major depressive disorder (MDD) is a prevalent, burdensome and frequently comorbid 
psychiatric condition (Charara et al., 2017), associated with reduced quality of life and 
impaired cognitive functioning (Corruble & Guelfi, n.d.; Papakostas, 2014).  
Despite several compounds being approved for the treatment of MDD, roughly half of affected 
patients report an inadequate response to first-line antidepressant treatment (Papakostas, 
Nielsen, Dragheim, & Tonnoir, 2018). Moreover, even though antidepressants represent the 
cornerstone in the treatment of MDD, available therapies often show several side effects (Rizvi 
& Kennedy, 2011). Consequently, many depressed patients fail to remit after an initial 
antidepressant trial, often deciding to stop treatment and requiring an additional treatment 
switch (Rush et al., 2006). With respect to bipolar depression, this represents the most 
pervasive and difficult to treat phase of bipolar disorder (Galimberti et al., 2019) and, even 
though the utility of antidepressants in bipolar depression is still debated, they are largely used 
as augmentative agents for the treatment of bipolar depression (Dell’Osso et al., 2020). 
Ultimately, depressive episodes often occur in other psychiatric disorders (i.e. personality 
disorders or eating disorders, or obsessive compulsive disorder) as comorbidity and could 
complicate the course of primary illness (De Carlo, Calati, & Serretti, 2016; Lochner et al., 
2014; Zheng et al., 2019).  
New generations of antidepressants aim at optimizing treatment efficacy and tolerability. 
Vortioxetine is, for instance, a novel antidepressant with multimodal activity (Papakostas et 
al., 2018), approved for the treatment of MDD in the last decade in many Countries worldwide 
(EMA (European Medicines Agency), n.d.; FDA, 2013). Its mechanism of action combines the 
inhibition of the serotonin transporter and the direct modulation of serotonin (5-HT) receptor 
activity, being it a 5-HT1A receptor agonist, a 5-HT1B receptor partial agonist, a 5-HT3, a 5-
HT7, and a 5-HT1D receptor antagonist and an inhibitor of the 5-HT transporter (Bang-
Andersen et al., 2011). Vortioxetine’ safety, tolerability and therapeutic action over affective 
symptoms have been addressed by several studies (Berhan & Barker, 2014; Jacobsen, 
Harper, Chrones, Chan, & Mahableshwarkar, 2015), conducted with low (up to 10 mg/day) 
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(Alam, Jacobsen, Chen, Serenko, & Mahableshwarkar, 2014; Baldwin, Hansen, & Florea, 
2012) and higher dosages (15-20 mg/day) (Jacobsen, Mahableshwarkar, Serenko, Chan, & 
Trivedi, 2015). Moreover, this compound was found to be effective in the treatment of cognitive 
dysfunction of depression (Pehrson et al., 2015), in light of its pro-cognitive effects (Salagre, 
Grande, Solé, Sanchez-Moreno, & Vieta, n.d.). Furthermore, vortioxetine’ side effects differ 
from those of other antidepressants, according to the low incidence of sexual dysfunction and 
weight gain (Salagre et al., n.d.). Conversely, reports of gastrointestinal side effects, 
particularly nausea, seem to be highly associated with vortioxetine, mainly at the beginning of 
the treatment (Hughes, Lacasse, Fuller, & Spaulding-Givens, 2017). 
In the available literature, there is a limited amount of real world studies evaluating potential 
differences in terms of effectiveness, tolerability and dropout rate between patients treated 
with low vs higher daily doses of vortioxetine.  
Therefore, the present naturalistic study aimed to characterize effectiveness and tolerability of 
vortioxetine in the real world, focusing on discontinuation rates and related reasons, in a 
sample of patients with other psychiatric and medical comorbidities, receiving mono and poly-
therapies and different dosages of vortioxetine. 
Given that investigation of the aforementioned variables in the real world is substantially 
limited, we did not formulate any a priori hypothesis, in terms of effectiveness, tolerability and 
dropout rates in the total sample and across differential low vs higher dosage groups, also 
considering that vortioxetine was frequently administered in patients with poly-comorbidity, 
poly-therapy, long duration of illness and previous exposure to other antidepressants. 
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2. MATERIAL AND METHODS 
2.1. Sample selection  
For the present observational study, 66 patients attending the psychiatric outpatient service of 
the Department of Mental Health of the Ospedale Luigi Sacco in Milan (Italy), were recruited.  
After receiving a full explanation of the protocol, all patients gave their informed consent for 
participating to the study. 
Data were gathered directly from patients, assessed by psychiatrists or residents in psychiatry 
with specific training in mood disorders management, through a semi-structured interview 
based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) (APA 
American Psychiatric, 2013), in order to ascertain psychiatric diagnoses and comorbidities, or 
through a retrospective review of patients’ medical records from October 2015 to February 
2019. In some cases, the interview took place with the presence of patients’ relatives or 
caregivers, with their consent. 
Eligible patients were adults (over age 18 years), with an ongoing Major Depressive Episode 
(MDE), according to the DSM-5 criteria (APA American Psychiatric, 2013) at the moment of 
the first vortioxetine prescription. The MDE could be related to a primary diagnosis of MDD or 
represent a comorbid condition. Indeed, patients could have a primary diagnosis of affective 
disorders (i.e., MDD-, Bipolar Disorder 1 or 2 -BD 1 or 2-), Anxiety Disorders (Generalized 
Anxiety Disorder -GAD-, Panic Disorder -PD-), Obsessive Compulsive Disorder -OCD-, 
Personality Disorders -PerD-, or another primary diagnosis (Adjustment Disorders –AD-, 
Eating Disorders -ED-). Exclusion criteria included: age <18 years old, the presence of brain 
diseases, mental retardation and psychiatric disorders secondary to a medical condition. 
Patients with different dosages of vortioxetine in the range of 5-20 mg/day and different 
regimens in terms of unique versus multiple daily administration were included. Socio-
demographic and clinical variables included: gender, age, age at onset, duration of illness, 
duration of untreated illness (DUI, defined as the time interval, in months, elapsing between 
the onset of the disorder and the administration of the first pharmacological treatment, in 
compliant patients, at an appropriate dosage and for an adequate period of time, in agreement 
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with recently updated International Treatment Guidelines) (Bauer et al., 2013; Grunze et al., 
2013), primary psychiatric diagnosis, psychiatric and medical comorbidities, psychiatric family 
history, prevalence and  lifetime number of hospitalization, dosage and side effects of 
vortioxetine, and associated poly-therapy.  
2.2. Assessment 
Over three subsequent evaluations, the first one of which taking place when vortioxetine was 
started (T0), then after four weeks (T1) and after 3 months (T2), the following psychometric 
scales were administered: Hamilton Depression Rating Scale – 21 items (HAMD-21) 
(HAMILTON, 1967), Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery & 
Asberg, 1979), Hamilton Anxiety Rating Scale (HAM-A) (HAMILTON, 1959), Young Mania 
Rating Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978), Clinical Global Impression-
Efficacy Index (CGI) (W., 1976), Dosage Record Treatment Emergent Symptom Scale 
(DOTES) (Guy W, 1976) and Treatment Emergent Symptoms Write-In Scale (TWIS). We 
considered as response ≥50% decrease of HAM-D total score at T1 or T2, while as remission 
HAMD≤7 total score (De Carlo et al., 2016) at the end of follow up. Dropouts at T2 were not 
taken into account for statistical analysis related to remission rates, while dropouts at T1 were 
excluded for analysis on response rate. 
2.3. Statistical analysis 
Descriptive analyses of the total sample and comparative ones (i.e. vortioxetine low vs higher 
daily dosages, dropout vs not, combined antidepressant vs not) were performed, using χ2 
tests for categorical variables and t test for continuous ones. Moreover, the response and 
remission rates in the total sample and across different groups of dosage were investigated. 
A two-tailed significance threshold was set at p < 0.05. Furthermore, repeated measures 
ANOVA for psychometric scales were carried out on the total sample and across different 
groups of dosage (vortioxetine≤ 10 mg vs >10 mg <15 mg vs ≥15 mg, 20 mg vs other dosages, 
20 mg vs ≤ 10 mg). In case of a missing outcome value, due to dropout, the last observation 
was carried forward (LOCF analysis) for the qualitative analysis. Statistical analyses were 
performed using Statistical Package for the Social Sciences (SPSS), version 19. 
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3. RESULTS 
3.1. Sample description 
The main sociodemographic and clinical variables of the study sample (n=66) are summarized 
in Table 1.  
The sample showed a mean age of 35.26 ± 16.31 years and a gender distribution of 36.4% 
men and 63.6% women. The mean DUI of the total sample was 36.70 ± 66.35 months, the 
mean age at illness onset was 35.26 ± 16.31 years and the mean duration of illness was 15.02 
±.10.42 years.  
Most common primary diagnoses were MDD (45.5%) and BD (33.4%), with an overall 
comorbidity rate of 48.5% in the overall sample. The 31.8% of the recruited patients reported 
at least one lifetime hospitalization.  
Associated medications were present in the 89.4% of the total sample and remained stable 
across the follow up. Furthermore, the 87.9% of the patients had been previously treated with 
other antidepressants.  
The total sample showed a mean vortioxetine daily dosage of 12.90 ± 5.65 mg (range 5-20 
mg), and the 33.3% (N=22) of the total sample could reach the highest dose of 20 mg/day.  
3.2. Effectiveness 
Repeated measures ANOVA highlighted a significant improvement of HAM-D, MADRS, HAM-
A, YMRS and CGI-efficacy index across time (Table 2 and Figure 2a). No significant 
differences emerged from a comparison between groups of patients treated with different daily 
dosages of vortioxetine (≤ 10 mg vs > 10 mg, <15 mg vs ≥15 mg, 20 mg vs other dosage, 20 
mg vs ≤ 10 mg), in terms of effectiveness (Table 2). However, a statistically non significant 
trend of association between increasing dosages of vortioxetine and higher improvements on 
psychometric scales was observed. Response and remission rates of 51.5% (N=34/57) and 
36.4% (N=24/42), respectively, were found in the total sample, without any significant 
difference, comparing different groups of daily dosages (Table 3, Figure 2b). 
3.3. Tolerability  
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Overall, 2/3 of the total sample could tolerate vortioxetine without reporting any side effect. 
Indeed, side effects were reported by the 33.3% of the total sample: respectively represented 
by gastrointestinal side effects (mainly nausea, vomit and diarrhea) in the 72.7% of them and 
gastrointestinal side effects associated with other side effects (mainly headache and sweating) 
in the 22.7%. of them. The main duration of side effects was 37.17 ± 33.12 days with 
moderate-severe (72.8%) or mild (27.3%) severity, measured through the DOTES and the 
TWIS. The association between reported side effects and vortioxetine was considered 
probable in the 90.9% of patients, remote or only possible in the rest of the sample on the 
basis of TWIS.  
Comparative analyses did not show any differences in terms of tolerability across distinct 
groups (i.e. vortioxetine ≤10 mg vs >10 mg, dropout vs not, associated antidepressant vs not) 
and, therefore, were not reported. 
3.4. Dropout 
Overall two thirds of the total sample could complete the entire follow-up. Approximately 1/3 
of the total sample (36.4%, N=24) dropped out, respectively 13.6% at T1 and 22.8% at T2. 
The reasons for dropout were: side effects (37.5%), lack of efficacy (29.2%), manic switch 
(12.5%), more than one reason (12.5%), others (e.g. personal decision, 8.3%). 
Therefore, in the 37.5% of the dropouts, treatment needed to be stopped because of low 
tolerability issues. These data are reported in Table 1 and represented in Figures 1a and 1b. 
Moreover, after splitting dropouts in two additional subgroups (at T1 and T2), it was found that 
most of patients dropping out at T1, discontinued for side effects (62.5%), while, considering 
dropouts at T2, the main reason of discontinuation was lack of efficacy (37.5%), followed by 
persistence of side effects (25.0%). 
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4. DISCUSSION  
 
The present naturalistic study aimed to characterize effectiveness, tolerability and dropout 
rates of vortioxetine in a sample of patients with a MDE in the real world (e.g. with 
comorbidities and concomitant treatments).  
4.1. Effectiveness 
An overall significant improvement of HAM-D, MADRS, HAM-A, YMRS and CGI-efficacy index 
across time points was observed, in line with the available literature (Baldwin, Chrones, et al., 
2016; Baldwin, Florea, Jacobsen, Zhong, & Nomikos, 2016; Nomikos, Tomori, Zhong, Affinito, 
& Palo, 2017). In particular, in a systematic review and network meta-analysis, comparing 
efficacy and acceptability of 21 antidepressant drugs, vortioxetine, together with agomelatine, 
amitriptyline, escitalopram, mirtazapine, paroxetine and venlafaxine were found to be more 
effective than other assessed antidepressants (Cipriani et al., 2018). However, studies 
specifically examining the effectiveness of vortioxetine in the real world are limited (Alvarez, 
Perez, Dragheim, Loft, & Artigas, 2012; Baldwin, Loft, & Dragheim, 2012; Boulenger, Loft, & 
Olsen, 2014; Henigsberg, Mahableshwarkar, Jacobsen, Chen, & Thase, 2012; Jain, 
Mahableshwarkar, Jacobsen, Chen, & Thase, 2013; Katona, Hansen, & Olsen, 2012; 
Mahableshwarkar, Jacobsen, & Chen, 2013; Pae et al., 2015). Therefore, the specific purpose 
of the present study was to characterize the effectiveness profile of vortioxetine in a real world 
sample of patients with poly-comorbidity, poly-therapy, long duration of illness and previous 
exposure to other antidepressants. 
In terms of vortioxetine dosage, no significant differences emerged from a comparison 
between groups of different dosages in relation to effectiveness and only a statistically non 
significant trend of association between increasing dosages of vortioxetine and higher 
improvements on psychometric scales was observed. Probably, the presence of poly-
comorbidity and poly-therapy in our sample could be the reason of this finding. Indeed, a meta-
analysis of studies with vortioxetine (5–20 mg/day) showed a significant dose-relationship in 
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the clinical effect, particularly for the overall increasing effect size associated with higher doses 
(Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, 2016).  
Such an effect could depend on the higher percentage of occupancy of the serotonin 
transporter (Areberg, Luntang-Jensen, Søgaard, & Nilausen, 2012). On the other hand, the 
efficacy of vortioxetine at lower dosage (5 mg) was supported by the trial in elderly patients 
with MDD (Katona et al., 2012), in particular in case of depressive symptoms associated with 
mild cognitive impairment (Cumbo, Cumbo, Torregrossa, & Migliore, 2019). In addition, it could 
be hypothesized that, when other psychotropic drugs, particularly antidepressants, are 
associated with vortioxetine, like in the majority of our sample, lower dosages might be 
necessary to show clinical improvements. Furthermore, it could be hypothesized that the non 
significant trend of efficacy with higher dosages observed, could have become statistically 
significant with a larger sample. 
4.2. Tolerability 
Overall, two thirds of recruited patients did not report any side effects, while, in the other third, 
the 72.7% experimented gastrointestinal side effects (mainly nausea, vomit and diarrhea) and 
the 22.7% gastrointestinal ones associated with other side effects (mainly headache and 
sweating). Indeed, It is well established that vortioxetine’s most common side effect is nausea 
(affecting more than 1 in 10 people) (EMA (European Medicines Agency), n.d.; McIntyre, 
2017), generally with mild or moderate severity related with high dosage and usually 
decreasing or extinguishing in few weeks (de Bartolomeis, Fagiolini, & Maina, 2016). In the 
same direction, the duration of side effects, in the present study, slightly exceeded four weeks 
(37.17 ± 33.12 days): conversely, the reported severity of side effects was moderate-severe 
(36.4% moderate, 36.4% severe) and a worse tolerability was not associated with high doses 
of vortioxetine. Moreover, no weight gain emerged in our sample, in line with other published 
placebo-controlled trials and open label extension studies with vortioxetine (Baldwin, Chrones, 
et al., 2016). This aspect represents an important feature of this drug, for both young and 
elderly patients, avoiding negative metabolic effects and related reasons of treatment 
discontinuation (Salagre et al., n.d.). Furthermore, vortioxetine showed a favourable profile in 
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terms of sexual side effects in the studied sample: only one patient (4.5%) reported this 
specific side effect and we could not exclude that it was related to other concomitant treatment. 
Also in other studies with vortioxetine, sexual dysfunction rates were low (Baldwin, Chrones, 
et al., 2016; McIntyre, 2017). Although in the present studies no significant differences among 
vortioxetine dosage groups were observed, in other trials, sexual dysfunction was found to be 
more frequent with higher doses, but always lower than those of Selective Serotonin Reuptake 
Inhibitors (SSRIs) (Jacobsen, Mahableshwarkar, Chen, Chrones, & Clayton, 2015). Thus, 
switching treatment with SSRI to vortioxetine showed an important advantage for patients 
experiencing sexual dysfunction due to SSRIs (Jacobsen, Mahableshwarkar, Chen, et al., 
2015). It represents a valuable feature of vortioxetine, since sexual side effects are very 
common among other antidepressants and often cause reduced adherence to treatment 
(Serretti & Chiesa, 2009).  
4.3. Dropouts  
The overall literature found vortioxetine to be one of the most tolerable antidepressants, 
associated with the lowest rate of drop-out (Cipriani et al., 2018). In our sample, approximately 
one third (36.4%, N=24) dropped out. In particular, most patients dropping out at T1 
discontinued for side effects (62.5%, N=5), probably because they could not reach T2 for the 
impacting side effects: on the other hand, considering dropouts at T2, the main reason of 
discontinuation was the lack of efficacy (37.5%, N=6) and, secondly, the persistence of side 
effects (25.0%, N=4). The possible explanation could be that subjects who reached T2 without 
a full response to vortioxetine, discontinued for the persistence of depressive symptoms. Our 
study could not investigate whether a slow titration (i.e. through drops) of vortioxetine could 
have reduced the rate of dropouts, due to side effects, and ultimately increased the rate of 
patients completing the entire follow-up. 
4.4. Limitations  
In the present study some limitations should be taken into account in the interpretation of the 
aforementioned findings. First, the limited recruited study sample, then the following 
methodological limitations should be considered. For example, referring to collected socio-
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demographic and clinical variables, the presence of recall bias cannot be excluded, particularly 
for patients with most remote onset, as well as the retrospective collection bias from previous 
medical charts. Moreover, our sample showed different illness severities and most of patients 
had previously been exposed to other antidepressants. Furthermore, the presence of poly-
comorbidities (both medical and psychiatric), concomitant treatments in the majority of the 
sample and different dosages of vortioxetine and /or different regimens in terms of unique 
versus multiple daily administration and finally a different titration process, might have 
ultimately conditioned the vortioxetine efficacy as well as the onset of side effects and dropout 
rates.   
 
5. CONCLUSION 
In conclusion, the present report confirms vortioxetine’s effectiveness over affective 
symptoms, along with a favorable tolerability profile and low dropout rates, independently from 
daily dosages, in a sample of patients with poly-comorbidities and poly-therapy. 
In order to assess whether higher dosages of vortioxetine can determine a larger quantitative 
and qualitative responses, maintaining a favorable tolerability profile, larger samples and 
further studies are warranted in the real world, including patients with poly-comorbidity, poly-
therapy, long duration of illness and previous exposure to other antidepressants. 
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TABLES 
 
Table 1. Main socio-demographic and clinical features of the study sample and profile of 
vortioxetine tolerability.  
 
Total sample N=66 
Gender 
Male 36.4% (N=24) 
Associated 
therapy* 
Antidepressants yes/no 33.3%(N=22) 
Female 63.6% (N=42) Stabilizers yes/no 54.5%(N=36) 
Age 50.20 ± 15.81 Benzodiazepinesyes/no 37.9%(N=25) 
Age at onset 35.26 ± 16.31 Antipsychotics yes/no 51.5%(N=34) 
Vortioxetine 
dosage 
12.9 ± 5.65 
Side effects (SE) 
Yes 33.3%(N=22) 
20 mg 33.3%(N=22) No 66.7%(N=44) 
< 15 mg 57.58%(N=38) SE duration 37.17 ± 33.12 days 
≥ 15 mg 42.42%(N=28) SE association 
(DOTES-
TWIS) 
Remote 4.5%(N=1) 
≤ 10 mg 56.1%(N=37) Possibile 4.5%(N=1) 
> 10 mg 43.9%(N=29) Probable 90.9%(N=20) 
Psychiatric 
primary diagnosis 
MDD 45.5%(N=30) 
SE severity 
Mild 27.3%(N=6) 
BD 1  7.6%(N=5) Moderate 36.4%(N=8) 
BD 2 25.8%(N=17) Severe 36.4%(N=8) 
GAD 7.6%(N=5) 
Type of SE ** 
Gastrointestinal(GI)  72.7%(N=16) 
PD 3.0%(N=2) ↓ Libido  4.5%(N=1) 
OCD 4.5%(N=3) GI + other  22.7%(N=5) 
PerD 1.5%(N=1) 
Dropout 
Yes 36.4%(N=24) 
Other 4.5%(N=3) No 63.6%(N=42) 
Psychiatric family 
history 
Yes 62.1%(N=41) 
Reasons of 
dropout 
Side effects 37.5%(N=9) 
No 37.9%(N=25) Non efficacy  29.2%(N=7) 
Psychiatric 
comorbidities 
Yes 48.5%(N= 32) Manic switch  12.5%(N=3) 
No 51.5%(N=34) Others 8.3%(N=2) 
Medical 
comorbidity 
Yes 62.1%(N=41) > 1 reason 12.5%(N=3) 
No 37.9%(N=25) DUI 36.70 ± 66.35 
Hospitalization 
Yes 31.8%(N=21) Previous 
antidepressant 
Yes 87.9%(N=58) 
No 68.2%(N=45) No 12.1%(N=8) 
Response rate*** 51.5% (N=34) Duration of 
illness (years) 
15.02 ±.10.42 
Remission rate*** 36.4% (N=24) 
 
*the total percentage could exceed 100, because the same patient could have different associated treatments. 
**Percentages are related to the total of 22 patients reporting side effects (33.3% of the total sample). 
*** Dropouts at T1 were not taken into account for statistical analysis related to remission rates, while dropouts both at T1 and 
T2 were excluded for analysis on response rate. 
Values are represented as mean ±SD.  
MDD= major depressive disorder, BD= bipolar disorder, GAD= generalized anxiety disorder, PD= panic disorder, OCD= 
obsessive compulsive disorder, PerD= personality disorders, SE= side effects, DUI= duration of untreated illness.  
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Table 2. Psychometric evaluation across time points for the total sample and different dosage 
subgroups. 
   T0 T1 T2 P 
HAMD 
Total sample N=66 20.17 ± 5.77 15.55 ± 6.17 11.30 ± 7.10 0.000 
Vortioxetine ≤10 mg N=37 20.68 ± 5.83 15.22 ± 6.12 11.30 ± 7.67 
0.947 
Vortioxetine >10 mg N=29 19.52 ± 5.74 15.97 ± 6.32 11.31 ± 6.43 
Vortioxetine <15 mg N=38 20.53 ± 5.82 15.37 ± 6.11 11.55 ± 7.72 
0.688 
Vortioxetine ≥15 mg N=28 19.68 ± 5.77 16.00 ± 6.43 11.18 ± 6.50 
Vortioxetine 20 mg N=22 18.68 ± 3.90 14.77 ± 4.05 9.95 ± 5.69 
0.693 
Vortioxetine < 20 mg N=44 20.91 ± 5.77 16.07 ± 7.04 12.11 ± 78 
Vortioxetine 20 mg N=22 18.68 ± 3.90 14.77 ± 4.05 9.95 ± 5.69 
0.683 
Vortioxetine ≤10 mg N=37 20.68 ± 5.83 15.38 ±6.19 11.46 ± 7.81 
Vortioxetine=single AD N=44 20.39 ± 6.19 16.25 ± 4.47  11.73 ± 7.31 
0.692 
Vortioxetine+other AD N=22 19.73 ± 4.94 14.41 ± 5.57 10.73 ± 7.05 
MADRS 
Total sample N=66 24.53 ± 5.71 19.50 ± 6.35 14.88 ± 7.64 0.000 
Vortioxetine ≤10 mg N=37 24.59 ± 5.97 18.54 ± 6.44 14.24 ± 8.08 
0.714 
Vortioxetine >10 mg N=29 24.45 ± 5.46 20.72 ± 6.11 15.69 ± 7.10 
Vortioxetine <15 mg N=38 24.55 ± 5.90 18.63 ± 6.38 14.45 ± 8.07 
0.713 
Vortioxetine ≥15 mg N=28 24.53 ± 5.71 20.68 ± 6.22 15.46 ± 7.12 
Vortioxetine 20 mg N=22 23.73 ± 4.10 19.68 ± 4.28 14.23 ±6.82 
0.717 
Vortioxetine < 20 mg N=44 24.53 ± 6.37 19.41 ±7.20 15.20 ± 8.08 
Vortioxetine 20 mg N=22 23.73 ± 4.10 19.68 ± 4.28 14.23 ±6.82 
0.708 
Vortioxetine ≤10 mg N=37 24.59 ± 5.97 18.54 ± 6.44 14.24 ± 8.08 
Vortioxetine=single AD N=44 24.98 ± 5.94 20.48 ± 6.32 15.39 ± 7.91 
0.715 
Vortioxetine+other AD N=22 23.64 ± 5.22 17.55 ± 6.06 13.86 ± 7.15 
HAMA 
Total sample N=66 14.83 ± 5.27 11.65 ± 5.26 8.62 ± 5.62 0.000 
Vortioxetine ≤10 mg N=37 14.86 ± 5.38 11.32 ± 5.01 8.46 ± 5.87 
0.761 
Vortioxetine >10 mg N=29 14.79 ± 5.22 12.07 ± 5.62 8.83 ± 5.38 
Vortioxetine <15 mg N=38 14.76 ± 5.35 11.32 ± 4.94 8.53 ± 5.81 
0.729 
Vortioxetine ≥15 mg N=28 14.93 ± 5.27 12.11 ± 5.72 8.75 ± 5.46 
Vortioxetine 20 mg N=22 14.00 ± 4.45 10.82 ± 4.48 7.59 ± 4.62 
0.732 
Vortioxetine < 20 mg N=44 15.25 ± 5.64 12.07 ± 5.61 9.14 ± 6.05 
Vortioxetine 20 mg N=22 14.00 ± 4.45 10.82 ± 4.48 7.59 ± 4.62 
0.726 
Vortioxetine ≤10 mg N=37 14.86 ± 5.38 11.32 ± 5.01 8.46 ± 5.87 
Vortioxetine=single AD N=44 15.25 ± 5.45 12.23 ± 5.37 8.84 ± 5.54 
0.729 
Vortioxetine+other AD N=22 14.00 ± 4.91 10.50 ± 4.95 8.18 ± 5.89 
YMRS 
Total sample N=66 2.65 ± 1.52 2.27 ± 1.87 1.71 ± 1.92 0.000 
Vortioxetine ≤10 mg N=37 2.76 ± 1.55 2.38 ± 2.11 1.78 ± 2.25 
0.976 
Vortioxetine >10 mg N=29 2.52 ± 1.50 2.14 ± 1.53 1.62 ± 1.43 
Vortioxetine <15 mg N=38 2.68 ± 1.60 2.32 ± 2.12 1.74 ± 2.24 
0.729 
Vortioxetine ≥15 mg N=28 2.61 ± 1.45 2.21 ± 1.50 1.75 ± 1.38 
Vortioxetine 20 mg N=22 2.58 ± 1.37 2.18 ± 1.47 1.73 ±1.39 
0.729 
Vortioxetine < 20 mg N=44 2.68 ± 1.61 2.32 ± 2.06 1.75 ± 1.14 
Vortioxetine 20 mg N=22 2.58 ± 1.37 2.18 ± 1.47 1.73 ±1.39 
0.721 
Vortioxetine ≤10 mg N=37 2.76 ± 1.55 2.38 ± 2.11 1.78 ± 2.25 
Vortioxetine=single AD N=44 2.77 ± 1.61 2.50 ± 2.11 1.98 ± 2.18 
0.732 
Vortioxetine+other AD N=22 2.41 ± 1.33 1.82 ± 1.18 1.27 ± 1.08 
CGI – 
Efficacy 
Index 
Total sample N=66 - 1.75 ± 1.19 2.35 ± 1.58 0.000 
Vortioxetine ≤10 mg N=37 - 1.74 ± 1.34 2.32 ± 1.68 
0.973 
Vortioxetine >10 mg N=29 - 1.75 ± 0.99 2.39 ± 1.48 
Vortioxetine <15 mg N=38 - 1.72 ± 1.32 1.77 ± 0.99 
0.803 
Vortioxetine ≥15 mg N=28 - 2.29 ± 1.67 2.48 ± 1.48 
Vortioxetine 20 mg N=22 - 1.91 ± 0.97 2.64 ± 1.43 
0.806 
Vortioxetine < 20 mg N=44 - 1.66 ± 1.29 2.24 ± 1.65 
Vortioxetine 20 mg N=22 - 1.91 ± 0.97 2.64 ± 1.43 
0.830 
Vortioxetine ≤10 mg N=37 - 1.74 ± 1.34 2.32 ± 1.68 
Vortioxetine=single AD N=44 - 1.75 ± 1.15 2.41 ± 1.57 
0.802 
Vortioxetine+other AD N=22 - 1.74 ± 1.28 2.29 ± 1.64 
 
T0 = when vortioxetine was started, T1 = after four weeks, T2 = after 3 months. HAM-D = Hamilton Depression Rating Scale, 
MADRS = Montgomery-Asberg Depression Rating Scale, HAM-A = Hamilton Anxiety Rating Scale, YMRS = Young Mania Rating 
Scale, CGI-Efficacy Index = Clinical Global Impression-Efficacy Index. “Vortioxetine=single AD”: patients treated with vortioxetine 
as single antidepressant (in association with other psychopharmacological class or not). “Vortioxetine+other AD”: patients treated 
with vortioxetine together with other antidepressants (in association with other psychopharmacological class or not).  
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Table 3. Response and remission rates in the total sample and comparing different dosage 
subgroups 
 
 Total sample 
Response  51.5% (N=34/57) 
Remission  36.4% (N=24/42) 
 Vortioxetine 20mg Vortioxetine≤10mg 
Response yes 60.0% (N=12, tot=20) 66.7% (N=20, tot=30) 
Response no 40.0% (N=8, tot=20) 33.3% (N=10, tot=30) 
Remission yes 58.8% (N=10, tot=17) 66.7% (N=14, tot=21) 
Remission no 41.2% (N=7, tot=17) 33.3% (N=7, tot=21) 
 Vortioxetine 20 mg Vortioxetine < 20 mg 
Response yes 60.0% (N=12, tot=20) 59.5% (N=22, tot=37) 
Response no 40.0% (N=8, tot=20) 40.5% (N=15, tot=37) 
Remission yes 58.8% (N=10, tot=17) 56.0% (N=14, tot=25) 
Remission no 41.2% (N=7, tot=17) 44.0% (N=11, tot=25) 
 Vortioxetine ≥15 mg Vortioxetine <15 mg 
Response yes 53.8% (N=14, tot=26) 64.5% (N=20, tot=31) 
Response no 46.2% (N=12, tot=26) 35.5% (N=11, tot=31) 
Remission yes 47.6% (N=10, tot=21) 66.7% (N=14, tot=21) 
Remission no 52.4% (N=11, tot=21) 33.3% (N=7, tot=21) 
 Vortioxetine >10 mg Vortioxetine ≤10 mg 
Response yes 51.9% (N=14, tot=27) 66.7% (N=20, tot=30) 
Response no 48.1% (N=13, tot=27) 33.3% (N=10, tot=30) 
Remission yes 47.6% (N=10, tot=21) 66.7% (N=14, tot=21) 
Remission no 52.4% (N=11, tot=21) 33.3% (N=7, tot=21) 
Dropouts at T2 were not taken into account for statistical analysis related to remission rates (percentage referred to 57 patients 
completing the entire follow-up), while dropouts at T1 were excluded for analysis on response rate (percentage referred to 42 
patients completing at least the T1 evaluation). 
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FIGURES 
 
Figure 1. a) Side effects rate and type of side effects; b) Drop out rate and reasons of drop out.  
 
 
1a) Side effects rate and type of side effects 
 
                          
 
 
 
 
 
1b) Drop out rate and reasons of drop out 
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Figure 2. Results of quantitative and qualitative analysis. 
 
2a) Psychometric evaluations across time points for the total sample  
 
T0 = when vortioxetine was started, T1 = after four weeks, T2 = after 3 months. HAM-D = Hamilton Depression Rating Scale, 
MADRS = Montgomery-Asberg Depression Rating Scale, HAM-A = Hamilton Anxiety Rating Scale, YMRS = Young Mania Rating 
Scale, CGI-Efficacy Index = Clinical Global Impression-Efficacy Index 
2b) Remission and response rates in the total sample.  
 
 
Dropouts at T2 were not taken into account for statistical analysis related to remission rates, while dropouts at T1 were excluded 
for analysis on response rate. Remission percentage is referred to the 42 patients who completed T2 evaluations, while response 
percentage is referred to the 57 patients who completed at least T1 evaluations. 
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